Dexcom (DXCM) Liabilities and Shareholders Equity (2016 - 2026)
Dexcom has reported Liabilities and Shareholders Equity over the past 17 years, most recently at $6.6 billion for Q1 2026.
- Quarterly Liabilities and Shareholders Equity fell 1.75% to $6.6 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $27.8 billion through Mar 2026, up 5.35% year-over-year, with the annual reading at $6.3 billion for FY2025, 2.23% down from the prior year.
- Liabilities and Shareholders Equity was $6.6 billion for Q1 2026 at Dexcom, up from $6.3 billion in the prior quarter.
- Over five years, Liabilities and Shareholders Equity peaked at $7.5 billion in Q3 2025 and troughed at $4.9 billion in Q3 2022.
- The 5-year median for Liabilities and Shareholders Equity is $6.5 billion (2024), against an average of $6.3 billion.
- Year-over-year, Liabilities and Shareholders Equity surged 34.64% in 2023 and then dropped 3.67% in 2024.
- A 5-year view of Liabilities and Shareholders Equity shows it stood at $5.4 billion in 2022, then increased by 16.19% to $6.3 billion in 2023, then increased by 3.51% to $6.5 billion in 2024, then fell by 2.23% to $6.3 billion in 2025, then grew by 4.63% to $6.6 billion in 2026.
- Per Business Quant, the three most recent readings for DXCM's Liabilities and Shareholders Equity are $6.6 billion (Q1 2026), $6.3 billion (Q4 2025), and $7.5 billion (Q3 2025).